We could not find any results for:
Make sure your spelling is correct or try broadening your search.
- Adds Two Rare Disease Medicines and Further Diversifies Company Revenue - ...
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Raptor Pharmaceutical Corp. -RPTP PR Newswire BALA CYNWYD, Pa., Sept. 20, 2016 BALA...
RAPTOR PHARMACEUTICAL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Raptor Pharmaceutical Corp. (RPTP) Over the Proposed Sale of the Company to Horizon Pharma...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Raptor Pharmaceutical Corp. (“Raptor”) (NASDAQ: RPTP) stock prior to...
Raptor Pharmaceutical Corp. Acquisition May Not Be in the Best Interests of RPTP Shareholders PR Newswire NEW YORK, Sept. 13, 2016 NEW YORK, Sept. 13, 2016 /PRNewswire/ -- WeissLaw LLP is...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Raptor Pharmaceutical Corp. (NASDAQ: RPTP) by Horizon Pharma plc (NASDAQ: HZNP). On September...
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board...
Rigrodsky & Long, P.A.: Do you own shares of Raptor Pharmaceutical Corp. (NASDAQ GM: RPTP)? Did you purchase any of your shares prior to September 12, 2016? Do you think the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions